EPErica Pool

Erica Pool

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Erica Pool has a total of 71 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Attitudes, knowledge, facilitators, and barriers to doxycycline post-exposure prophylaxis for sexually transmitted infections among gay and bisexual men who have sex with men and trans-gender women: A mixed-methods scoping review

    by Fergal Fouhy, George Budden, Erica Pool, Manik Kohli

    Background: As doxycycline post-exposure prophylaxis (doxyPEP) implementation for bacterial STI prevention expands among gay, bisexual and other men who have sex with men (GBMSM) and transgender women (TGW), this scoping review synthesised community knowledge, attitudes, barriers, facilitators and practices to inform guidelines and support uptake. Methods: This scoping review followed JBI methodology and was reported per PRISMA-ScR. Three databases (Embase, Medline/PubMed, Web of Science) were searched for articles on community perspectives of doxyPEP among GBMSM and TGW published from 2013 to 2025. Included studies were screened, data extracted using inductive coding, and analysed thematically. Factors were mapped onto the Knowledge, Attitudes, and Practices (KAP) Model. Results: 24 studies (18,428 participants) met inclusion criteria, (North America (n = 12), Europe (n = 6), Asia (n = 3), Oceania (n = 3)). Most were quantitative (n = 20), with two qualitative and two mixed-methods studies, recruiting primarily via online/app-based surveys or from sexual health clinics. Five coding categories emerged: awareness and knowledge; previous use; willingness to try; barriers and concerns; and facilitators and predictors. Awareness and prior use were low and heterogenous (ranging from 17 to 67%), yet willingness was moderate to high (12% to 90%), particularly after brief education and when free of charge. Prior use remained limited (2.5-36%). Predictors of interest included prior STI diagnosis, HIV PrEP use, living with HIV, multiple sexual partners, condomless sex, and higher educational attainment. Side effects and antimicrobial resistance (AMR) were the primary concerns. Conclusions: Clinicians and sexual health services should prioritise opportunistic doxyPEP offers to those with recent STIs, HIV PrEP use, or HIV, embedding education and low/no-cost access within routine care to close the awareness-uptake gap. Public health bodies should invest in robust AMR surveillance alongside implementation, and community-based education should directly address side-effect concerns. Extending research and delivery models to under-represented groups is also needed to ensure equitable, evidence-based uptake.

  • Therapeutic drug monitoring of tenofovir disoproxil and emtricitabine in oral HIV pre-exposure prophylaxis (PrEP) users who have undergone gastrointestinal surgery

    by Muhammad Azam Ismail, Victoria Tittle, Rachael Jones, Hannah Loftus, Nicolo Girometti, Olamide Dosekun, Katrina Stegmann, Erica Pool, Shema Tariq, Anna Nakamura, et al.

    Objectives: Oral HIV pre-exposure prophylaxis (PrEP) is highly effective in preventing HIV, but its efficacy depends on adequate absorption of drug, which may decrease following gastrointestinal surgery. Methods: Clinicians across eight Genito-urinary Medicine clinics in the United Kingdom submitted data on PrEP users with history of gastrointestinal surgery who were referred to a national complex PrEP multi-disciplinary team between June 2021 and April 2023. Anonymised data were submitted on demographics, surgical history, PrEP regimen, and results of therapeutic drug monitoring (TDM) and HIV screening tests. Descriptive analyses were performed in SPSS version 29. Results: Nine cases described cis-gender men-who-have-sex-with-men (MSM) with median age of 47.4 years (IQR = 43 – 56.5) taking tenofovir disoproxil (TDF)/emtricitabine (FTC) daily ( n = 8) or event-based ( n = 1) as PrEP. Median time between PrEP initiation and TDM was 53 days (IQR = 8.5–1705). The mean (±SD) trough concentration of tenofovir (TFV) and FTC were 90.2 ± 27.7 ng/mL and 76.0 ± 45.9 ng/mL, respectively. All patients had a negative HIV test at follow-up. Conclusions: Plasma trough concentrations of TFV observed in our cohort taking TDF/FTC were above the expected concentrations associated with PrEP efficacy as previously described in the literature, suggesting that PrEP can be safely given in this population, with TDM used for reassurance.

  • Open Access

    Association between health-related quality of life and menopausal status and symptoms in women living with HIV aged 45–60 years in England: An analysis of the PRIME study

    by Hajra Okhai, Livia Dragomir, Erica Rm Pool, Caroline A Sabin, Alec Miners, Lorraine Sherr, Katharina Haag, Rageshri Dhairyawan, Nina Vora, Binta Sultan, et al.

    Objectives: The aim of this study was to compare the health-related quality of life between mid-life women with HIV and the general population and to investigate the association between health-related quality of life and menopausal (1) status and (2) symptoms among women with HIV. Methods: Cross-sectional data of women with HIV aged 45–60 years from the Positive Transitions Through the Menopause Study. Health-related quality of life was assessed using the Euroqol questionnaire with utility scores categorizing health as perfect (score = 1.00), sub-optimal (0.75–0.99) or poor (< 0.75). Scores were compared between Positive Transitions Through the Menopause study participants and women (aged 45–59 years) from the Health Survey for England. Associations between health-related quality of life and menopausal status/symptoms in Positive Transitions Through the Menopause participants were assessed using a multivariable two-part regression model, the results of which are combined to produce a single marginal effect. Results: In total, 813 women from the Positive Transitions Through the Menopause study were included (median age 49 (interquartile range: 47–53) years); the majority were of Black African ethnicity (72.2%). Overall, 20.9%, 43.7% and 35.3% of women were pre-, peri- and post-menopausal, respectively, and 69.7% experienced mild/moderate/severe menopausal symptoms. Approximately, 40% reported perfect health, 22.1% sub-optimal health and 39.0% poor health, similar to women from the Health Survey for England (perfect health: 36.9%, sub-optimal health: 25.2%, poor health: 37.9%). In multivariable models, we found an association between health-related quality of life and peri-menopausal status (marginal effect: 0.07 (0.02, 0.12)); however, the association with post-menopausal status was attenuated (marginal effect: 0.01 (–0.05, 0.06)). There remained a strong association between lower utility scores and moderate (marginal effect: 0.16 (0.11, 0.20)) and severe (marginal effect: 0.32 (0.27, 0.39)) menopausal symptoms. Conclusion: There were no differences in health-related quality of life between women with HIV (Positive Transitions Through the Menopause participants) and women from the Health Survey for England dataset. Among Positive Transitions Through the Menopause participants, health-related quality of life was reduced in peri-menopausal women and those with increasingly severe menopausal symptoms. Our findings highlight the importance of proactive assessment of menopausal status and symptoms to optimize health-related quality of life in women living with HIV as they reach mid-life and beyond.


  • Open Access

    Use of a Retrospective Methodology to Examine the Process of Care Surrounding Serious Medical Events in HIV-Positive Patients: A Feasibility Study

    by Erica R M Pool, Vanessa Cooper, Elaney Youssef, Juliet Wright, Jordan Skittrall, Ola Blach, Martin Fisher, Helen Smith

    Introduction: Comorbidities are increasingly common among people living with HIV (PLWH) as they age. There is no evidence regarding models of care. We aimed to assess feasibility of a novel methodology to investigate care processes for serious medical events in PLWH. Method: The method was based on the National Confidential Enquiry into Patient Outcome and Death (NCEPOD). Data were extracted from medical records and questionnaires completed by general practitioners (GPs), HIV physicians, and non-HIV specialist physicians. A panel reviewed anonymized cases and gave feedback on the review process. Results: Eleven of 13 patients consented to the study. Questionnaires were completed by 64% of HIV physicians, 67% of non-HIV specialist physicians, and 55% of GPs. The independent review panel (IRP) advised improvement in the methodology including data presentation and timing. Conclusion: This method was acceptable to patients and secondary care physicians. Further work is needed to the improve GP responses and facilitate IRP.


  • Open Access

    High‐risk behaviours, and their associations with mental health, adherence to antiretroviral therapy and HIV parameters, in HIV‐positive men who have sex with men

    by Erm Pool, A Winston, E Bagkeris, Jh Vera, Pwg Mallon, M Sachikonye, Fa Post, A Pozniak, M Boffito, J Anderson, et al.

    Objectives: To investigate the patterns and frequency of multiple risk behaviours (alcohol, drugs, smoking, higher risk sexual activity) among men who have sex with men (MSM) living with HIV.Methods: Cross sectional study.Results: 147 out of 819 HIV‐positive MSM exhibited a high‐risk phenotype (defined as >3 of smoking, excess alcohol, sexually transmitted infection and recent recreational drug use). This phenotype was associated with younger age, depressive symptoms and <90% adherence in multivariable logistic regression.Conclusion: In a cohort of MSM, a small, but significant proportion exhibited multiple concurrent risk behaviours.


  • Posterior reversible encephalopathy syndrome in HIV-positive patients: a case report and literature review

    by Erica Rm Pool, Michael Porte, Nigel Durham, Sue Urwin, Paul Laboi, Fabiola Martin

    We are reporting the case of a woman who was admitted acutely to our intensive care unit without any collateral history. She was diagnosed with posterior reversible encephalopathy syndrome (PRES) as a consequence of poor adherence to anti-hypertensive, anti-diabetic and anti-retroviral medications. PRES is a rare condition, which may cause cortical blindness; contrary to its name it is not always reversible. Rapid diagnosis and aggressive management of underlying causes facilitate reversibility of PRES. We also summarise the literature on patients with HIV and PRES.


  • HIV testing for hospital inpatients in a priority area

    by Erica Pool

    Welcome to the largest platform for early-stage research

  • Interventions for tobacco use cessation in people living with HIV and AIDS

    by Erica R M Pool, Omara Dogar, Ryan P Lindsay, Peter Weatherburn, Kamran Siddiqi

    Tobacco use is highly prevalent amongst people living with HIV/AIDS (PLWHA) and has a substantial impact on morbidity and mortality. To assess the effectiveness of interventions to motivate and assist tobacco use cessation for people living with HIV/AIDS (PLWHA), and to evaluate the risks of any harms associated with those interventions. We searched the Cochrane Tobacco Addiction Group's Specialised Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, and PsycINFO in June 2015. We also searched EThOS, ProQuest, four clinical trial registries, reference lists of articles, and searched for conference abstracts using Web of Science and handsearched speciality conference databases. Controlled trials of behavioural or pharmacological interventions for tobacco cessation for PLWHA. Two review authors independently extracted all data using a standardised electronic data collection form. They extracted data on the nature of the intervention, participants, and proportion achieving abstinence and they contacted study authors to obtain missing information. We collected data on long-term (greater than or equal to six months) and short-term (less than six months) outcomes. Where appropriate, we performed meta-analysis and estimated the pooled effects using the Mantel-Haenszel fixed-effect method. Two authors independently assessed and reported the risk of bias according to prespecified criteria. We identified 14 studies relevant to this review, of which we included 12 in a meta-analysis (n = 2087). All studies provided an intervention combining behavioural support and pharmacotherapy, and in most studies this was compared to a less intensive control, typically comprising a brief behavioural intervention plus pharmacotherapy. There was moderate quality evidence from six studies for the long-term abstinence outcome, which showed no evidence of effect for more intense cessation interventions: (risk ratio (RR) 1.00, 95% confidence interval (CI) 0.72 to 1.39) with no evidence of heterogeneity (I2 = 0%). The pooled long-term abstinence was 8% in both intervention and control conditions. There was very low quality evidence from 11 studies that more intense tobacco cessation interventions were effective in achieving short-term abstinence (RR 1.51, 95% CI 1.15 to 2.00); there was moderate heterogeneity (I2 = 42%). Abstinence in the control group at short-term follow-up was 8% (n = 67/848) and in the intervention group was 13% (n = 118/937). The effect of tailoring the intervention for PLWHA was unclear. We further investigated the effect of intensity of behavioural intervention via number of sessions and total duration of contact. We failed to detect evidence of a difference in effect according to either measure of intensity, although there were few studies in each subgroup. It was not possible to perform the planned analysis of adverse events or HIV outcomes since these were not reported in more than one study. There is moderate quality evidence that combined tobacco cessation interventions provide similar outcomes to controls in PLWHA in the long-term. There is very low quality evidence that combined tobacco cessation interventions were effective in helping PLWHA achieve short-term abstinence. Despite this, tobacco cessation interventions should be offered to PLWHA, since even non-sustained periods of abstinence have proven benefits. Further large, well designed studies of cessation interventions for PLWHA are needed.